Last update June 29, 2022

Reboxetine Mesylate

Compatible

Safe substance and/or breastfeeding is the best option.

It is a selective and potent norepinephrine reuptake inhibitor used in the treatment of depression. Oral administration twice daily.

It is excreted in breast milk in clinically insignificant amounts (Hackett 2006) and no problems have been observed in infants whose mothers have taken it. (Berlin 2019, Hackett 2006)

Plasma levels in these infants were very low. (Hackett 2006)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.


See below the information of this related product:

  • Maternal Depression (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Reboxetine Mesylate in other languages or writings:

Groups

Reboxetine Mesylate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Reboxetine Mesylate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 %
Molecular weight 410 daltons
Protein Binding 98 %
VD 0.5 l/Kg
Tmax 2 hours
T½ 12.5 hours
Theoretical Dose 0.001 - 0.002 mg/Kg/d
Relative Dose 2 (1.4 - 2.5) %

References

  1. Pfizer. Reboxetine. Drug Summary. 2022 Full text (in our servers)
  2. Berlin M, Kronenfeld N, Dinavitser N, Brik A, Cohen R, Ofek F, Wiener Y, Berkovitch M. The safety of reboxetine during pregnancy and lactation − A case series. Reprod Toxicol 2019;88:138. Abstract #15. doi:10.1016/j.reprotox.2019.05.025.
  3. AEMPS. Reboxetina. Ficha técnica. 2016 Full text (in our servers)
  4. Berle JO, Spigset O. Antidepressant Use During Breastfeeding. Curr Womens Health Rev. 2011 Abstract Full text (link to original source) Full text (in our servers)
  5. Hackett LP, Ilett KF, Rampono J, Kristensen JH, Kohan R. Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant. Eur J Clin Pharmacol. 2006 Abstract

Total visits

4,014

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM